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peptide Assembly on the 
Membrane Determines the 
HIV-1 Inhibitory Activity of Dual-
Targeting Fusion Inhibitor Peptides
Maria J. Gomara1, Yolanda perez2, Javier P. Martinez3, Ramon Barnadas-Rodriguez5, 
Anke Schultz6, Hagen von Briesen6, Alex Peralvarez-Marin  5, Andreas Meyerhans  3,4 & 
Isabel Haro1
Novel strategies in the design of HIV-1 fusion/entry inhibitors are based on the construction of dual-
targeting fusion proteins and peptides with synergistic antiviral effects. In this work we describe the 
design of dual-targeting peptides composed of peptide domains of E2 and E1 envelope proteins from 
Human Pegivirus with the aim of targeting both the loop region and the fusion peptide domains of 
HIV-1 gp41. In a previous work, we described the inhibitory role of a highly conserved fragment of the 
E1 protein (domain 139–156) which interacts with the HIV-1 fusion peptide at the membrane level. 
Here, two different dual-targeting peptides, where this E1 peptide is located on the N- or the C-terminus 
respectively, have been chemically synthesized and their antiviral activities have been evaluated with 
HIV pseudotyped viruses from different clades. The study of the functional behaviour of peptides in a 
membranous environment attending to the peptide recognition of the target sites on gp41, the peptide 
conformation as well as the peptide affinity to the membrane, demonstrate that antiviral activity of 
the dual-targeting peptides is directly related to the peptide affinity and its subsequent assembly into 
the model membrane. The overall results point out to the necessity that fusion inhibitor peptides that 
specifically interfere with the N-terminal region of gp41 are embedded within the membrane in order to 
properly interact with their viral target.
Similarly as innovations in HIV-1 immunotherapy are focused on the design and engineering of bispecific anti-
bodies with two antigen-binding variable fragments of immunoglobulins that recognize two separate antigens, 
(reviewed by Ferrari et al.1), novel strategies in the design of HIV-1 fusion/entry inhibitors are based on the 
construction of dual-targeting fusion proteins and peptides with synergistic antiviral effects (reviewed by Castro 
et al.2). Examples of recombinant protein chimeras have been recently reported. Thus, recombinant protein chi-
meras produced by fusing lectins to peptides derived from the membrane-proximal external region of gp41 have 
been designed to target simultaneously gp120 and gp41 domains causing lytic inactivation of HIV-13,4. Moreover, 
in order to design HIV-1 fusion inhibitors with targeting properties to the precise site of HIV-1 entry, the C34 
peptide has been conjugated to anchoring molecules over-expressed on the cell surface such as co-receptors 
CCR5 or CXCR4. These recombinant protein chimeras have been expressed on the surface of T cell lines and 
primary CD4+ T cells, conferring particularly potent, broad and durable protection from HIV-1 infection to pri-
mary CD4+ T cells in vitro and in humanized mice5. In addition to recombinant proteins, dual-targeting peptide 
HIV-1 fusion inhibitors have also been described with the ability of binding simultaneously and cooperatively 
to different gp41 domains6–8. The rationale for the design of chimeric peptide fusion inhibitors is based on the 
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sequential nature of the HIV-1 virus-cell fusion process characterized by the appearance of multiple targets that 
are susceptible to inhibition. Thus, the combination of two different peptide fusion inhibitors in the same mol-
ecule theoretically implies a synergistic fusion inhibitory activity as well as a greater probability of avoiding the 
appearance of resistant virus.
GB virus type C (GBV-C), recently renamed as Human Pegivirus (HPgV)9, can be considered as a symbiont 
or commensal of humans since infections provide a beneficial effect on survival in HIV-1 positive subjects10. 
Previous work of our group demonstrated the antiviral properties of chimeric molecules composed of an E2 
region from GBV-C that targets the gp41 loop region and the peptide sequence of VIR576 that interacts with the 
gp41 fusion peptide (FP), both described as HIV-1 inhibitors7. Following the same approach, in this work the E2 
sequence has been combined with an 18-mer domain from the E1 protein that interacts with the gp41 fusion pep-
tide at the membrane level and has a broad spectrum activity against HIV-1, as we previously reported11. Trying 
to improve this anti-HIV-1 activity, two dual targeting peptides (DT-peptides), where the E1 peptide is on the 
N- or the C-terminus respectively, have been synthesized. The antiviral activities of the DT-peptides have been 
evaluated with HIV pseudotyped viruses from different clades.
Since HIV-1 gp41 glycoprotein is confined between the cellular and the viral membranes, the study of the 
physicochemical processes involved at this interface is essential to understand the mode of action of fusion inhib-
itor peptides12–14. As it has been previously reported, the interaction of fusion inhibitor peptides with biological 
membranes may be related to their inhibition efficiency15–17. Based on this background, in this work conforma-
tional and biophysical assays using model membranes have been carried out in order to understand better the 
requirements of DT-peptides for maintaining their functional behaviour as HIV-1 fusion inhibitors.
Results and Discussion
DT-peptides composed of two different sequences from E1 and E2 glycoproteins of the non-pathogenic HPgV 
have been synthesized with the purpose of targeting two different regions of HIV-1 gp41: the loop and the fusion 
peptide (FP) (Fig. 1).
To this aim, we have selected the peptide sequence comprising the (45–64) region from the N-terminal part 
of the E2 protein that has been described as a fusion inhibitor of the late HIV-1 entry steps via interaction with 
the disulphide loop region of HIV-1 gp4118. In addition, we have also selected the (139–156) region of the E1 
protein since recent structural studies carried out by our group have demonstrated the interaction of this peptide 
sequence with the HIV-1 FP at the membrane level interfering with the stabilization of the six-helix bundle for-
mation in a membranous environment19. Penetration of both E1 and E2 peptides in vaginal mucosa through their 
release from polymeric nanoparticles has been recently studied as a preliminary biopharmaceutical evaluation of 
their potential microbicidal usefulness20,21. Based on these two peptide sequences from the HPgV, described as 
fusion inhibitors, two different DT-peptides have been synthesized combining the sequences in different orienta-
tion through a Gly/Ser linker. Dual-targeting peptide 1 (DT-P1) contains the E1 sequence on C-terminus whereas 
dual-targeting peptide 2 (DT-P2) contains the E1 sequence on N-terminus of the chimeric peptide. The primary 
structure of DT-peptides is detailed in Fig. 1.
The anti-HIV activities of DT-peptides and E1 were comparatively tested against a set of viral pseudotypes 
carrying HIV envelopes from HIV subtype A, B, C and A/E (Table 1) in the TZM-bl reporter cell line. Table 2 
shows the effective concentration 50 (EC50) values of E1, DT-P1 and DT-P2 peptides.
Figure 1. Schematic representation of the corresponding target sites on HIV-1 gp41 glycoprotein of the 
selected peptide inhibitors: HPgV (45–64) E2 peptide and HPgV (139–156) E1 peptide. Primary sequences of 
the DT-peptides, DT-P1 and DT-P2, are depicted at the bottom of the figure.
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Both DT-peptides demonstrated similar antiviral activities against all pseudotypes in the low micromolar 
range although they were between 2 and 10 times less active than the single E1 peptide. Neither of the peptides 
showed cell toxicity at the tested concentrations. To get further on the functional behavior of DT-peptides respon-
sible for the lower activity, conformational and biophysical studies have been carried out. Three different issues 
on the peptides have been taken into account that might be directly related to the antiviral activity: the peptide 
recognition of the target sites on gp41, the peptide conformation adopted in a membranous environment and the 
peptide affinity to the membrane.
DT-P2 maintains better recognition of both gp41 target sites than DT-P1. The capability of 
preserving the recognition of target sites on gp41 by both DT-P1 and DT-P2 was first studied. As previously 
reported7,18, to specifically study the target site of the E2 peptide for DT-peptides we have used a competitive 
immunoassay using the specific gp41-targeting mAb (F240) that recognize the disulfide loop region on gp41 
glycoprotein. As it is shown in Fig. 2a, both DT-peptides didn’t inhibit similarly the specific recognition of the 
truncated recombinant gp41MN by the mAb F240. Although, DT-P2 was able to compete with the mAb F240 in 
the recognition of the disulfide loop region in a dose-dependent manner, the inhibition of mAb binding to the 
gp41 by DT-P1 was significantly lower than that reported for the single E2 peptide. Thus, DT-P2 maintains, at 
Type Name Tropism Subtype
NIH 
cat#
SHORT 
ID
Backbone pSG3ΔEnv* 11051
Env pHXB2 X4 B 1069 HXB2
Env pAC10.0 R5 B 11024 AC10
Env pQ461.e2 R5 A 10460 Q46
Env pQ23.17 R5 A 10455 Q23
Env pCAP210.2 R5 C 11317 CAP2
Env pCM235/GS R5 A/E 7701 CM235
Table 1. Plasmids used to produce the HIV pseudotypes that express the described envelope protein. 
Pseudotypes were produced by plasmid co-transfections in 293T cells as described by Martínez et al.39. *HIV 
expression vector that expresses all HIV-1 proteins except Env and Vpu. For all pseudotypes: TZM-bl cells 
were infected with a virus inoculum corresponding to a RLU/s of 10-fold higher than RLU/s in control cells; 
RLU/s = Relative Light Units per second.
E1 DT-P1 DT-P2
EC50 SEM EC50 SEM EC50 SEM
HXB2 2.49 0.40 7.63 0.88 10.77 1.03
AC10 3.93 0.59 20.18 1.31 14.02 1.15
Q461 2.71 0.43 24.46 1.39 24.49 1.39
Q23 6.65 0.82 21.62 1.34 15.86 1.20
CAP210 1.12 0.30 12.94 0.43 9.40 0.43
CM235 8.78 0.94 18.93 1.28 17.94 1.25
Table 2. EC50 values (in µM) of the peptides against a panel of HIV pseudotypes carrying different envelopes.
Figure 2. Comparative study of interaction of the DT-peptides with the HIV-1 gp41 target domains: gp41 
loop and FP. (a) Inhibition of the mAb (F240) binding to immobilized gp41MN induced by DT-peptides and E2 
peptide in a competitive assay. (b) Inhibitory effect of DT-P1, DT-P2 and E1 peptides on haemolysis induced by 
the HIV-1 FP. Y axis represents the percentage of haemolysis expressed relative to the total haemolysis caused by 
the respective HIV-1 FP alone.
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the highest concentration, the recognition of the target of the original E2 peptide, whereas DT-P1 decreases its 
interaction capability with the disulfide loop region on gp41.
The target site of the E1 peptide fusion inhibitor, which is the HIV-1 FP (AVGIGALFLGFLGAAGSTMGARS), 
has also been studied for the DT-peptides. We have tested the recognition of both DT-peptides with the HIV-1 
FP by means of the haemolysis assay. Although both DT-peptides were able to inhibit haemolysis induced by the 
FP to some extent at the highest concentrations (Fig. 2b), the inhibition pattern of DT-P2 was more similar to 
that previously reported for the E1 peptide fusion inhibitor11. The highest concentration tested of DT-P2 (5 µM) 
inhibited 70% whereas DT-P1 only inhibited 25% of haemolysis induced by FP.
To deep delve in the recognition of the FP as a target site by the DT-peptides, a Fluorescence Resonance 
Energy Transfer (FRET) assay was performed22. To this end, both DT-peptides were labeled on solid phase 
with 5(6)-carboxy-tetramethyl-rhodamine (TAMRA) at the N-terminus. The HIV-1 FP labeled with 
6-(7-nitrobenzofurazan-4-ylamino) hexanoic acid (NBD) was used as a donor peptide. The fluorescence 
assay was assessed in a membranous environment using POPG liposomes as model membrane. As depicted 
in Fig. 3b, increased concentrations of TAMRA-DT-P2 resulted in a decrease of the maximal emission wave-
length (λem = 544 nm) of NBD upon excitation at λex = 467 nm, as well as an increase in the maximal emission of 
rhodamine (580 nm). These results demonstrated that there is an energy transfer from the donor-peptide to the 
acceptor-peptide due to the association between the HIV-1 FP and the DT-P2.
This energy transfer was considerably smaller when the FRET assay was carried out in POPC liposomes 
(Fig. 3d). As reported, HIV-1 FP shows an α-helical conformation in POPG vesicles at a 1:200 peptide:lipid ratio 
while adopts an extended structure in POPC membranes23. HIV-1 FP inserts deeply as an α-helix into the hydro-
phobic core of POPG membrane bilayer and lies on the surface of the lipid bilayer as extended conformation in 
POPC liposomes24. This different conformational behavior of HIV-1 FP depending on the membrane lipid com-
position, among other factors such as peptide to lipid molar ratio and concentration of divalent cations, has been 
related to its physiological activity25. Thus, the overall results of the FRET assays pointed out that the association 
between DT-P2 and FP is closer when the FP is embedded in the membrane in an α-helix conformation.
On the other hand, the fluorescence assay showed that the energy transfer between the NBD-FP and the 
TAMRA-DT-P1 was significantly lower in both POPG (Fig. 3a) and POPC (Fig. 3c) liposomes. Accordingly to the 
Figure 3. Fluorescence spectra of donor NBD-FP (0.5 µM) (black solid line) and acceptor labelled peptide 
mixtures in liposomes (100 uM) at concentrations ranging from 0.15 µM (grey solid line) to 1.5 µM (black 
dotted line). Acceptor labeled peptides: (a) TAMRA-DT-P1 in POPG liposomes; (b) TAMRA-DT-P2 in POPG 
liposomes; (c) TAMRA-DT-P1 in POPC liposomes; (d) TAMRA-DT-P2 in POPC liposomes.
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results of the haemolysis assay, the interaction of DT-P1 with the HIV-1 FP is minor and consequently, the DT-P1 
is less able to maintain the target site of the original E1 peptide sequence.
Taking together the FRET results for DT-peptides and comparing their FRET efficiencies with the ones pre-
viously reported for the E1 peptide11, the association between FP and E1 peptide is significantly closer than that 
between FP and DT-P2. The energy transfer efficiency between FP and E1 peptide at a donor:acceptor 1:1 ratio, 
was around 30% while the energy transfer efficiency between FP and DT-P2 was only 5%.
The overall described biophysical assays demonstrated that DT-P2 maintains better the recognition of both 
gp41 target sites than DT-P1 but not as efficiently as the single E1 peptide. These results might explain the lower 
antiviral activity of DT-P1 and to some extent the loss of activity of DT-P2. To understand the lower efficiency 
of DT peptides in the recognition of the gp41 target sites and consequently their different functional behavior, 
conformational studies of the peptides on the membrane environment have been next carried out.
DT-P2 resembles better the conformation of the E1 peptide in micelles. Previously reported 
computer-based structural analysis of the N-terminal part of the E2 protein demonstrated that the region that 
comprises the E2 peptide does not contain significant amounts of regular secondary structure and is rather flexi-
ble to interact with the disulfide loop of gp41 during HIV-1 entry18. By contrast, structure-activity studies carried 
out previously by our group have confirmed the importance of some structural elements in the anti-HIV-1 activ-
ity of the shorter inhibitor E1 peptide19. As previously determined in our group using NMR spectroscopy, E1 pep-
tide is embedded and adopts a helix-turn-helix secondary structure in presence of DPC-d38 micelles. We decided 
to evaluate if the modification of E1 peptide in N- and C-terminal ends with E2-GGGS/GGGS-E2 sequences 
could affect the E1 main secondary structure. To assess qualitatively the structural changes, I-Tasser Server to 
predict secondary structure, conformational analysis by attenuated total reflection Fourier Transform Infrared 
spectroscopy (ATR-FTIR) in the presence of phosphatidylcholine (PC) vesicles and evaluation of 1D 1H NMR 
spectra of the DT-peptides in zwitterionic micelles were used26. First, the secondary structure prediction showed 
that in both peptides, the E1 moiety conserves the helix-coil-helix secondary structure (Supplementary Fig. S5). 
Second, in the presence of phosphatidylcholine (PC) the ATR-FTIR second derivative spectra indicated that both 
peptides show a characteristic α-helix peak position at 1650 cm−1 (Fig. 4).
Third, regarding NMR the appearance of both tryptophan and aromatics regions in the DT-P2 peptide 1H 
spectrum in the presence of 50 mM DPC micelles (Fig. 5) was very similar from that for E1 peptide (Fig. 5). The 
E1 moiety in DT-P2 showed a similar chemical shift dispersion/pattern of tryptophan indole NH protons and 
Phe/Tyr aromatic protons, in particular Phe-13 aromatic protons (in E1P47 nomenclature) upfield shift when dis-
solved in presence of 50 mM DPC micelles19,27. Comparing the NMR spectra of peptides DT-P1 and DT-P2, the 
spectrum of the former peptide displayed more broadened resonances, as was observed for the loss of chemical 
shit dispersion for tryptophan side chain NH protons, thereby suggesting an increased aggregation state of this 
peptide in micelles. To increase solubility, higher amounts of DMSO-d6 were used in the final NMR sample (from 
3 to 13%), but no improvement was observed.
To evaluate the aggregation state of both peptides, the translational diffusion coefficients were measured by 
NMR at low (0.5 mM) concentration for both peptides in 10 mM phosphate buffer (pH = 6.0, in 100% D2O: 
0.5 mM DSS and 1.0 mM TCEP) with 50 mM DPC-d38 (Table 3). NMR measurements showed that the value 
of self-diffusion coefficients obtained for DT peptides is in the expected range for a peptide of similar length 
Figure 4. Absorbance second derivative of ATR-FTIR spectra for the C = O stretch and amide I regions for 
liposomes in the absence (grey line) and in presence of DT-P1 (red line) and DT-P2 (blue line) peptides in 
dry films. Since the peptide:lipid ratio (1:130) is prone to mask peptide secondary structures, we have used 
the second derivative of ATR-FTIR to highlight different secondary structures due to mathematical band 
narrowing. The intense peak at 1685 cm−1 indicates the presence of TFA, used as counter-ion in peptide 
synthesis. The dotted lines indicate the wavenumber position of regions of interest.
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associated to micelles19,28. The diffusion coefficient of DT-P1 peptide decreases in comparison with the value 
measured for DT-P2. Taking into account that both peptides have the same molecular weight, the slower dif-
fusion indicates that the radius/hydrodynamic volume of DT-P1 is bigger than DT-P2 and that DT-P1 is more 
aggregated in DPC micelles than DT-P2. Also, we observed a decrease in diffusion coefficients for DPC (CH2)n 
and –CH2-N+(CH3)3 protons from DT-P2/DPC to DT-P1/DPC, which could be indicative of bigger micelles in 
presence of more aggregated DT-P1 peptide.
In addition to the peptide conformation, it is relevant to carry out membrane affinity studies for the 
DT-peptides in order to understand their different functional behavior in relation to the E1 peptide.
Figure 5. 1D 1H NMR spectra of E1, DT-P1 and DT-P2 peptides in DPC micelles (15 mM HEPES-d11, 
pH = 6.0, 1 mM TCEP, in 87% H2O/13% DMSO-d6 or 87% H2O/10% D2O/3% DMSO-d6; 300 K). Phe-13 and 
Trp’s NH side chain assignment obtained from our previous work for E119 and tentative assignment for DT-P2 
peptide.
D (10−11 m2s−1) error
Sample DT-P1 + DPC (0.50:50 mM)
DT-P1a 5.28 1.14 × 10−14
DPCb 8.24 7.96 × 10−14
DPCc 7.88 3.77 × 10−14
Sample DT-P2 + DPC (0.50:50 mM)
DT-P2a 6.94 7.64 × 10−15
DPCb 8.90 1.03 × 10−14
DPCc 8.93 4.29 × 10−14
Table 3. Translational diffusion coefficient measured by NMR spectroscopy for peptide samples in DPC-d38 
(10 mM phosphate buffer pH = 6 in 100% D2O, 1 mM TCEP and 0.5 mM DSS; 300 K). aPeptides Aromatic 
region 7.23–7.13 ppm, bTwo components: CH2 DPC region 1.26–1.14 ppm (small D, from free + micellar DPC) 
and small MW contaminant (large D, see fittings in supplementary material). cCH2N+(CH3)3 DPC region 
3.49–3.53 ppm.
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DT-peptides loose the capability of assembly into the model membrane demonstrated by the 
E1 peptide. Membrane affinity was studied monitoring intrinsic fluorescence of tryptophan (Trp) residues 
after titration with unilamellar vesicles. Emission spectra of DT-peptides in buffer showed a maximum at a 
wavelength that was at least 10 nm blue-shifted related to the maximum emission of the soluble Trp derivative 
N-acetyltryptophanamide (NATA) indicating that Trp residues in both peptides are basically shielded from water. 
As illustrated in Fig. 6a, fluorescence intensity of Trp residues diminished after titration of DT-P1 with liposomes 
similarly as that of the Trp derivative (NATA) that was used to monitor the dilution effect after liposome titration. 
Unlike DT-P1, a fluorescence increase of the emission spectra of DT-P2 upon addition of POPC liposomes was 
observed (Fig. 6b). Nevertheless, the fluorescence increase of the Trp residues on the E1 peptide was higher at 
lower concentrations of lipid vesicles (Fig. 6c). The fractional change in peptide intrinsic fluorescence upon titra-
tion with liposomes represented in Fig. 6d demonstrated that although there is an interaction between DT-P2 
peptide and the lipid bilayer that affects the environment of the Trp residues, the E1 peptide partitioned stronger 
into lipid vesicles.
Collisional quenching of Trp by brominated phospholipids was used to assess the accessibility of the peptides 
to lipids. The quenching of Trp fluorescence by brominated lipids was examined after adding the peptides to 
lipid vesicles composed of 1,2-di-(9-10-dibromo)stearoyl-sn-glycero-3-phosphocholine and was evaluated by 
fluorescence comparison upon addition of the peptides to lipid vesicles composed of 1,2-dioleoyl-sn-glycero-3-p
hosphocholine. As shown in Fig. 7, both DT-peptides showed a limited accessibility for the lipids. On the con-
trary, Trp residues of the E1 peptide were highly quenched demonstrating greater peptide accessibility to the 
hydrophobic inner part of the lipid vesicles. This result is in agreement with previous structural NMR studies 
of the E1 inhibitor peptide in DPC micelles which indicated that it was lying parallel to the surface, with the 
Figure 6. Fluorescence emission spectra of DT-P1 (a), DT-P2 (b) and E1 peptide (c) upon titration with 
POPC unilamellar vesicles. Black solid line represents 5 µM peptide in HEPES buffer; grey and dotted lines 
corresponds to peptide titration with POPC LUVs at a concentration ranged from 0.05 mM to 0.6 mM; (d) 
Partitioning isotherms of E1 and DT-peptides estimated from the fractional change in Trp fluorescence 
intensity upon addition of increasing amounts of liposomes. Binding experiments were done by triplicate. 
Values of apparent mole fraction partition coefficients were: KX = 2.4 × 105 and KX = 8.2 × 105 for DT-P2 and E1 
peptide, respectively.
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negative-charged side chains oriented to the choline head group and the hydrophobic residues pointing to the 
micelle core19. Thus, the quenching of Trp residues of the E1 peptide by brominated atoms attached at positions 9 
and 10 of the hydrophobic tails of the lipid implies that these Trp residues point to the micelle core such as it was 
previously reported. On the contrary, DT-peptides lose the capability of being soaked inside the lipid vesicles.
As it was previously demonstrated19, the interaction between the E1 fusion inhibitor and its viral target (FP) 
takes place at the membrane level. The intrinsic fluorescent experiments point out to the necessity that fusion 
inhibitor peptides that specifically interfere with the N-terminal region of gp41 are embedded within the mem-
brane in order to interact properly with their viral target.
The conformational studies carried out in this work demonstrated that DT-P2, which has the E1 sequence on 
N-terminus, resembles better the helix-turn-helix structure of the E1 inhibitor and maintains better the recog-
nition of both gp41 target sites. The reduced affinity of DT-P1 for the gp41 target sites could be related to its ten-
dency to self-aggregate such as it was demonstrated by the translational diffusion coefficients measured by NMR. 
In order to reduce the peptide aggregation, longer and more hydrophilic linkers could be used to separate E1 and 
E2 sequences on novel modified DT- peptides. Taking into account that the two target regions are separated by 
the NHR in gp41, polyethylene glycol-based spacers of different lengths could also facilitate the simultaneous 
bind of DT-peptides to both targets. However, since the fusion process is progressive it is possible that there is no 
need to fix the distance between the two inhibitory domains.
Although DT-P2 is less prone to aggregation in micelles and preserve better the conformational features 
required for maintaining the antiviral activity than DT-P1, similar inhibition activities in both DT-peptides were 
found. Regarding the antiviral activity of the single E1 peptide, the lower inhibitory activity of both DT-peptides 
could be related with their lower interaction and assembly into the membrane phospholipids which impairs the 
recognition of the gp41 target site.
Conclusions
The study of the functional behavior of DT-peptides in a membranous environment attending to the peptide rec-
ognition of the target sites on gp41, the peptide conformation as well as the peptide affinity to the membrane, lead 
us to conclude that the lower antiviral activity of the DT-inhibitors compared to single peptides could be related 
to the peptide affinity and its subsequent assembly into the model membrane. Specifically, the insertion of the 
peptide into the lipid bilayer is a necessary condition for maintaining the recognition of the target sites, mainly 
the fusion peptide on gp41, and therefore is closely related to the antiviral activity. The overall results point out to 
the requirement that fusion inhibitor peptides that interfere with those domains in HIV-1, critical for stabilizing 
the six-helix bundle formation, are embedded into membranes in order to interact with their viral target.
Methods
The work was approved by the Ethical Committee of the Consejo Superior de Investigaciones Científicas (CSIC), 
Madrid, Spain. All methods were performed in accordance with the relevant guidelines and regulations of 
IQAC-CSIC.
Synthesis, characterization and purification of peptides. The dual-targeting-peptides were man-
ually synthesized by solid-phase peptide synthesis (SPPS) using 9-fluorenyl-methoxycarbonyl (Fmoc) strat-
egy. DT-P1 and DT-P2 were synthesized as C- terminal carboxamides. Elongation of both peptidyl-resins 
was carried out following the same procedure. Thus, couplings were performed by 2-(1H-7-azabenzotriazole-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate methanaminium (HATU) and diisopropylethylamine 
(DIPEA) activation, with a threefold molar excess of Fmoc-amino acids. Amino acid side chain protection was 
effected by the following: triphenylmethyl (Trt) for glutamine, asparagine and cysteine; tert-butyl (tBu) for aspar-
tic acid, glutamic acid, serine and tyrosine; 2,2,5,7,8-pentamethyl-chroman-6-sulfonyl (Pmc) for arginine; and 
tert-butoxycarbonyl (Boc) for lysine and tryptophan. The Fmoc deprotection step was performed twice with 
20% piperidine in dimethylformamide (DMF) for 10 min. The stepwise addition of each residue was assessed by 
Kaiser’s (ninhydrin) test and by the chloranil test for identification of secondary amines, when coupling proline 
residues.
Figure 7. Peptide Trp quenching by brominated lipid vesicles. Fractional quenching is shown as mean ± SD of 
three repeated assays.
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A fraction of the DT-P1 and DT-P2 peptidyl-resins were labelled at the N-terminus with 
5(6)-carboxy-tetramethyl-rhodamine (TAMRA), previously activated with N,N´-diisopropylcarbodiimide 
(DIPCDI) and 1-hydroxybenzotriazole (HOBt). The coupling reaction was carried out overnight with a threefold 
excess of the reagents.
The peptides were concomitantly side chain deprotected and cleaved from the resin by treatment with a mix-
ture of 94% (v/v) trifluroacetic acid (TFA), 1% (v/v) triisopropylsilane (TIS), 2.5% (v/v) 2-mercaptoethanol and 
2.5% (v/v) water for 3 h with occasional agitation at room temperature. The solvent was removed in vacuum and 
the crude peptides were precipitated with diethyl ether. The solids were dissolved in 30% acetic acid in water and 
lyophilized.
The crude peptides were purified by semipreparative HPLC in an XBridgeTM Prep C8 column (5 μm, 
10 × 250 mm, Waters). The identity of the peptides was confirmed by electrospray ionization mass spectrometry 
(ES-MS). ES-MS was performed with a liquid chromatograph–time of flight (LC-TOF) detector, LCT Premier 
XE (Micromass Waters, Milford, MA, USA), coupled to Analytical Ultra Performance Liquid Chromatography 
apparatus (UPLC, Waters). Samples were dissolved in a mixture of acetonitrile/water (1/1, v/v) and analysed in 
the UPLC at a flow rate of 0.3 mL/min. The mass spectra were recorded in positive ion mode in the m/z 500–2500 
range. UPLC was performed in an Acquity UPLC BEH C18 reverse-phase column (2.1 × 100 mm, 1.7 μm par-
ticle size) and with an Acquity UPLC (Waters) chromatograph. Solvent A was 20 mM formic acid in water and 
solvent B was 20 mM formic acid in acetonitrile. Elution was performed with linear gradients of 5–100% solvent 
B into A over 10 min at a flow rate of 0.3 mL/min. Characterization of the pure peptides ES-MS are shown in 
Supplementary Figs S1–S4. The peptides were 95% pure by analytical HPLC at 220 nm.
Competitive ELISA assays. Nunc MaxiSorp 96-microwell plates (Nunc, Roskilde, Denmark) were used as 
a support for coating a solution of 0.22 ug/ml of HIV-1 gp41MN protein in carbonate/bicarbonate buffer (0.1 M, 
pH 9.8) overnight at 4 °C. After blocking the wells with 1% (w/v) BSA in phosphate buffer, pH 7.2 with 0.1% 
Tween 20 for 1 h at room temperature, peptides diluted in phosphate buffer were added to each well at graded 
concentration. Simultaneously, a solution of F240 monoclonal antibody in phosphate buffer was added to the 
wells at a 0.04 µg/well concentration. The plates were incubated for one hour and a half at room temperature. After 
washing three times, anti-human IgG conjugated to peroxidase (Dako Denmark) diluted 1:6000 in phosphate 
buffer was incubated for 1 h at room temperature. Then, the o-phenylenediamine dihydrochloride was incubated 
for 30 min and the absorbance values were measured at a wavelength of 492 nm. The measurements were taken by 
triplicate in three different days. The results are expressed as the percentage of inhibition of gp41 binding induced 
by the peptide.
Haemolysis assay. The human care of the rabbits used to perform the haemolysis assay with blood samples 
was carried out according to the guidelines for animal care in the facilities of the IQAC-CSIC.
The procedure of the haemolysis assay was performed as described in ref. 11. Briefly, concentration solutions of 
1.25, 2.5 and 5 µM of each DT- peptide and 100 µM of HIV-1 FP were incubated for 60 min at 37 °C. Erythrocytes 
from rabbit, previously washed with PBS and diluted 1:10 in PBS, were added at a concentration of 10%(v/v) to 
the peptide solutions and incubated again 60 min at 37 °C. The solutions were centrifuged at 1000 g for 5 min and 
supernatants were transferred to a 96 well MaxisorpTM plate (Nunc). Absorbance was quantified at 405 nm. The 
percentage of haemolysis is expressed relative to the total haemolysis caused by the respective HIV-1 FP alone and 
is calculated as described in ref. 29. Each sample was processed in triplicate and on two different days. Haemolysis 
induced by each DT-peptide incubated with red blood cells without HIV-1 FP was also tested.
Fluorescence assays. Fluorescence assays were performed in a PTI Fluorescence Master Systems spectro-
fluorimeter (Photon Technology International) using a 1 cm path length quartz cuvette.
Unilamellar vesicles (LUV) composed of the negatively charged phospholipid 1-palmitoyl-
2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (POPG) or zwitteronic phospholipid palmitoyl
-2-oleoyl-sn-glycero-3-phosphocholine (POPC) (both from Avanti Polar-Lipids) were prepared as model mem-
branes. Lipids (10 mM) were dissolved in chloroform/methanol (2/1, v/v) solution. The solvent was evaporated 
under reduced pressure. A buffer solution of PBS 0.01 M pH 7.4 was added to the previously obtained lipid film to 
prompt the spontaneous formation of multilamellar vesicles that were subjected to a process of 10 freeze and thaw 
cycles. The liposomes were then subjected to an extrusion process through 100-nm pore-sized polycarbonate 
filters in a high-pressure extruder.
To perform fluorescence resonance energy transfer assays, NBD-labelled FP and TAMRA-labelled 
DT-peptides were used as donor and acceptor, respectively. The emission spectra were recorded in the wave-
length range 450–650 nm upon excitation at λ = 467 nm. NBD FP was added to a 100 µM suspension of LUVs 
to reach a final concentration of 0.5 µM. Then, TAMRA-labelled DT-peptides in doses ranging from 0.15 µM to 
1.5 µM were sequentially added to the LUV solutions containing the NBD-FP. Fluorescent measurements were 
recorded before and after de addition of TAMRA-labelled peptides and intensities were corrected by subtraction 
of the signal produced by the labelled acceptor alone. The contribution of the vesicles was subtracted from every 
measurement. The percentage efficiency of the energy transfer was determined from the ratio of the donor in the 
presence and the absence of the acceptor, at the wavelength of the maximal emission of the donor (λ = 530 nm)30.
To carry out membrane partition studies with DT-peptides, emission fluorescence spectra were recorded for 
DT-peptides in PBS (0.01 M, pH 7.4) at 20 °C using an excitation wavelength of 280 nm. Changes in the trypto-
phan (Trp) fluorescence spectra were monitored after incubation of 5 µM of each peptide with increasing con-
centrations of liposomes. The suspensions were continuously stirred and were left to equilibrate for 10 min before 
recording the spectra. Fluorescence intensities were corrected by subtraction of the vesicle blank. A lipid titration 
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of N-acetyltryptophanamide (NATA) was carried out at the same time. As described in ref. 31, the apparent mole 
fraction partition coefficients were determined by fitting the binding curves to the equation:
= + −F f F f F(1 )bound max bound 0
where F is the relative fluorescence intensity, F0 is the fluorescence intensity in the absence of lipid.
= +f K L W K L/( )bound x x
where Kx is the mole fraction partition coefficient, L is the lipid concentration, and W is the molar concentration 
of water (55.3 M at 25 °C).
Quenching of Trp by brominated phospholipid was performed using liposomes composed of 1,2-di-(9-
10-dibromo) stearoyl-sn-glycero-3-phosphocoline (Br-PC) (Avanti Polar Lipids). As previously reported32, this 
lipid has similar properties as unsaturated phosphatidylcholine chains due to the bulkiness of bromine residues. 
For this reason, liposomes of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) were used for comparing the 
Trp fluorescence of peptides with brominated liposomes. Liposomes were prepared following the same procedure 
as described above. Comparatively, a concentration of 2 µM of peptides was added to 200 µM of lipid vesicles 
either BrPC or DOPC. After 5 min of incubation at 25 °C, fluorescence spectra were recorded with an excitation 
wavelength of 290 nm and emission from 300 to 450 nm. The fractional quenching was calculated as reported in 
ref. 33 by (F0 − F)/F0, where F0 is the fluorescence intensity at 340 nm for peptides added to DOPC liposomes and 
F for peptides added to Br-PC liposomes.
For fluorescein leakage experiments, liposomes of soy bean phosphatidylcholine (PC) were prepared contain-
ing 60 mM fluorescein. At this concentration the dye exhibits autoquenching. Multilamellar liposomes, obtained 
after hydrating the lipid film with phosphate buffer 10 mM pH 7.4 containing 60 mM fluorescein, were extruded 
through 100 nm pore polycarbonate membranes. Non-entrapped fluorescein was removed by size exclusion chro-
matography using PD-10 columns with Sephadex G-25 (medium), eluted with phosphate buffer 10 mM pH 7.4 
containing 60 mM NaCl. Typically, a solution of purified liposomes of about 0.65 mM PC was obtained.
The effect of the peptides on the PC membranes was monitored by measuring the fluorescence of the purified 
liposomes after the addition of aliquots of DMSO solutions of peptides to a final peptide concentration of 2.5 µM 
(final DMSO content was 10% v/v). Since the addition of the peptides caused vesicle disruption, a scattering 
contribution to the very fluorescence signal was produced. Thus fluorescence could not be accurately measured 
for more than, approximately, 50 minutes. After incubation, Triton X-100 was added to the samples in order to 
solubilize any lipidic structure and to measure their total fluorescence. Results are expressed as % of entrapment 
using the following equation:
= – – –F F F F% entrapment 100 (1 ( )/( ))i f0 0
where F0, Ff and Fi are, respectively, the sample fluorescence at time 0, after Triton X-100 addition, and at time i.
Attenuated total reflection Fourier Transform Infrared (ATR-FTIR) experiments. 10 µL of 
fluorescein-free suspensions containing peptide mixed with liposomes (1:130) placed on top of the ATR ZnSe 
crystal, were gently dried under a N2 stream. Spectra were obtained at room temperature by the average of 2 
blocks of 250 scans each at 2 cm−1 resolution in a VARIAN FTS-7000 infrared spectrometer. The second deriva-
tive was performed with nine smoothing points.
NMR Spectroscopy. Nuclear magnetic resonance (NMR) spectra were recorded at 300 K on a Bruker 
Avance III console (Bruker Biospin, Germany) combined with a 9.7 T Oxford Instruments magnet (1H 500 MHz), 
equipped with a 5 mm inverse cryogenically cooled triple-resonance TCI (1H, 13C, 15N, and 2H lock) cryoprobe 
with a z-axis magnetic field-gradient capability. For proton spectra acquisition, peptide samples were prepared 
by dissolving first lyophilized peptide in a small amount of DMSO-d6 and next, dissolution in detergent solution 
containing perdeuterated DPC-d38 (final molar ratio ~ 1:100, peptide/DPC 0.5:50 mM). The final pH of peptide/
detergent aqueous solution (87% H20/10% D20/3% DMSO-d6 or 87% H20/13% DMSO-d6, 15 mM HEPES-d11) 
was adjusted to 6.2. Buffer solution included 1 mM of reducing agent Tris(2-carboxyethyl)phosphine hydrochlo-
ride (TCEP), to minimize aggregation by intermolecular disulfide bond formation. For diffusion coefficients 
determination, the field gradient strength (Gz) was calibrated by measuring the self-diffusion coefficient of resid-
ual H2O in a 100% 2H2O sample at 298.0 K. A diffusion coefficient of 1.91 × 10−9 m2 s−1 for the residual H2O 
signal was then used for the back calculation of the field gradient strength. Diffusion NMR experiments were 
acquired at 300 K to minimize convection effects. The stebpgp1s19 pulse sequence with WATERGATE 3919 for 
water suppression and one spoil gradient from Bruker library was used. The diffusion coefficient, D, was deter-
mined by fitting diffusion weighted intensities of selected peaks or integrals over a chosen range to the following 
equation
γ= − δ Δ − δI I Dexp{ g ( /3) }, (1)0
2 2 2
where γ is the gyromagnetic ratio of proton and g, δ and Δ are the amplitude, duration and separation of the sin-
gle pair of gradient pulses, respectively. Due to the use of bipolar gradient elements, Δ is replaced by (Δ − τ1/2) 
in Eq. (1), with τ1 being the time interval between the bipolar gradient pulses within the bipolar gradient encod-
ing or decoding segment. Fittings to Eq. (1) were performed using Bruker Dynamics Center software (Bruker 
Biospin, Germany), the results are reported below. In the case of DPC, the observed diffusion coefficient is the 
weighted average of the free (Dfree) and bound (Dbound) values and
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= +D f D f D , (2)obs free free bound bound
in which ffree and fbound are the mole fraction of free and micellar DPC. In our case, Dbound (DPC) = Dmic 
(DPC) ≅ Dmic (peptides). The reason for DPC diffusion coefficients being higher than peptides values is likely due 
to a surplus of free monomeric DPC molecules (below cmc), so the diffusion coefficient measured for DPC has a 
relevant contribution of DPC-free peptide, while the observed peptide resonances (and their diffusion coefficient) 
mainly correspond to DPC-bound peptide.
Virus preparation and titration. The preparation of the HIV-1 Env pseudotyped virus stocks in a GCLP- 
(Good Clinical Laboratory Practice) compliant manner occurred as described previously34. This includes the 
pseudoviruses listed in Table 2 with the Env sequences HXB2, AC10.0.29, Q461.e2, Q23.17, CAP210.2.00.E8 
and CM235.c11 as well as the Env deficient backbone plasmid pSG3ΔEnv. Within this study the titration assay 
to determine the virus dilution at a relative luminescence unit (RLU) of 150,000 was performed according to 
the method described before34–36 and the luminescence was measured using the Infinite F200 microplate reader.
tZM-bl Assay. The neutralization assay utilizing the TZM-bl cells was conducted to analyze lot-to-lot var-
iations of freshly prepared virus stocks as published by Montefiori in 200936,37. This is a modified version of the 
assay by Wei et al.38 and determine the Inhibitory Concentration providing 50 value (IC50 = 50% reduction of 
the RLU values compared to the virus control; half maximal inhibitory concentration) by measuring the lumi-
nescence with the Infinite F200 microplate reader. Within the assay a panel of five specified control reagents 
was assayed: sCD4 (Progenics Pharmaceutical, Tarrytown, USA), IgG1b12, 2F5, 4E10 and TriMab consisting of 
2G12, IgG1b12 and 2F5 (Polymun Scientific, Klosterneuburg, Austria) with an initial concentration of 25 µg/ml. 
The indicated concentration of the control reagents, which should lead to 50% neutralization, must agree within 
3-fold between the newly prepared virus stock and the reference virus for 80% of the tested reagents.
Cell viability and antiretroviral assays. Peptides were tested for their antiviral activities against a panel 
of HIV pseudotypes carrying different HIV envelope proteins (Table 2) in the TZM-bl indicator cell line. Briefly, 
10-fold serial dilutions of the compounds (0.001–10 µM) were incubated in duplicates with the cells in 96-well 
plates. 1 h after incubation, cell culture medium was replaced and cells were infected with the different pseudo-
types together with fresh compounds. TZM-bl cells were infected with a virus inoculum corresponding to relative 
light units (RLUs) of 10-fold higher than the background RLUs in control cells. 48 h after infection, cells were 
washed and luciferase was quantified using the Britelite Plus Luciferase Assay System (PerkinElmer). Luciferase 
values were normalized to DMSO control. Cell viability was estimated in parallel in non-infected TZM-bl cells 
with the Cell Titer Glo ATPase kit (Promega). CC50 and EC50 values ± SEM were calculated with GraphPad Prism, 
using the built-in function log (inhibitor) vs. normalized response.
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